# A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Source: https://onco.cc/trials/nct04570423/  
OnCo record `nct04570423` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Eflapegrastim in non-Hodgkin lymphoma, run by Spectrum Pharmaceuticals, Inc, now recruiting.

## Summary

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy is a phase 2 interventional study registered as NCT04570423 by Spectrum Pharmaceuticals, Inc, with 40 participants planned, started 2021-05-20 and due to reach its primary completion in 2027-10. Interventions recorded: Eflapegrastim and Chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04570423
- Phase: 2
- Setting: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
- Sponsor: Spectrum Pharmaceuticals, Inc
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT04570423: https://clinicaltrials.gov/study/NCT04570423

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Eflapegrastim](https://onco.cc/drugs/eflapegrastim/)
- companies: [Spectrum Pharmaceuticals](https://onco.cc/companies/spectrum-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct04570423.json